The latest edition of the HPRA Drug Safety Newsletter (DSN 110) includes important updates to support the safe and appropriate use of the following medicines:
- Janus Kinase inhibitors (JAKi). Recommendations to mitigate the risks of malignancy, major adverse cardiovascular events, serious infections, VTE and mortality when used to treat chronic inflammatory disorders.
- Gabapentin. Expanded warnings around abuse potential, dependence and withdrawal.
- Amoxicillin. Drug-induced enterocolitis syndrome (DIES)
- Product information updates recommended by the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)